AQNEURSA is the first ataxia-telangiectasia treatment. Can a 12-week improvement change a lifelong disease?
IntraBio’s AQNEURSA has become the first approved treatment for ataxia in people with ataxia-telangiectasia after a randomized Phase 3 trial showed a significant improvement in neurological function. The approval ends decades without a specific therapy for the disorder’s ataxia, but it does not resolve whether levacetylleucine can slow long-term neurodegeneration or alter the immune, pulmonary
